In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The ...

2024 saw massive interest in the radiopharmaceutical space, full of large-scale deal-making, as isotope producers struggle to meet inflated demand. Credit: Trairut Noppakaew/ Shutterstock A ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Aurora Pharmaceutical logo "Our sales team is the backbone of our customer relationships, and this expansion reflects both our business growth and our dedication to providing best-in-class service to ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...